Isotretinoin
- Generic Name
- Isotretinoin
- Brand Names
- Absorica, Accutane, Amnesteem, Claravis, Clarus, Epuris, Myorisan, Sotret, Zenatane
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28O2
- CAS Number
- 4759-48-2
- Unique Ingredient Identifier
- EH28UP18IF
- Background
Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne. It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States. The first isotretinoin-cont...
- Indication
Isotretinoin is indicated to treat severe recalcitrant nodular acne and patients ≥12 years enrolled in the iPLEDGE program.
- Associated Conditions
- Acne conglobata, Neuroblastoma (NB), Rosacea, Sezary Syndrome, Early Mycosis Fungoides (MF), Refractory Acne vulgaris, Severe Recalcitrant nodular acne
- Associated Therapies
- -
Impact of Isotretinoin in Different Doses on Quality of Life
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 100
- Registration Number
- NCT05316675
Effect of Oral Isotretinoin on The Level of SerumYKL40 in Acne Vulgaris Patients
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2022-09-06
- Lead Sponsor
- Alshimaa Abbas Mohamed Ebrahim
- Target Recruit Count
- 60
- Registration Number
- NCT05218486
- Locations
- 🇪🇬
Aswan university, Aswan, Egypt
A Companion Treatment Study for Patients With Moderate to Severe Acne Vulgaris
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Edward Lain, MD
- Target Recruit Count
- 31
- Registration Number
- NCT04940767
- Locations
- 🇺🇸
Austin Institute for Clinical Research, Inc., Pflugerville, Texas, United States
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Y-mAbs Therapeutics
- Registration Number
- NCT04909515
- Locations
- 🇷🇺
National Medical Research Center Pediatric Hematology, Oncology and Immunology n.a Dmitry Rogachev, Moscow, Russian Federation
🇸🇬ICON Cancer Centre Novena, Singapore, Singapore
🇷🇺Research Institute of Pediatric Oncology ad Hematology of N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
Effects of Isotretinoin on the Growth Rate and Thickness of the Nail Plate
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- Sinan Özçelik
- Target Recruit Count
- 70
- Registration Number
- NCT04660916
- Locations
- 🇹🇷
Balikesir University, Balıkesir, Turkey
Weekly Isotretinoin Therapy Study
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 22
- Registration Number
- NCT04594759
- Locations
- 🇺🇸
Samantha Karline, Charleston, South Carolina, United States
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed TomographyBiological: DinutuximabProcedure: FDG-Positron Emission TomographyRadiation: Iobenguane I-123Drug: IrinotecanDrug: IsotretinoinProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanBiological: SargramostimDrug: Temozolomide
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 41
- Registration Number
- NCT04385277
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
Relationship Between Serum Vitamin D Levels and Musculoskeletal Adverse Effects in Patients Using Isotretinoin
- Conditions
- Interventions
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Ankara Training and Research Hospital
- Target Recruit Count
- 177
- Registration Number
- NCT04204304
- Locations
- 🇹🇷
Ankara Training and Research Hospital, Ankara, Turkey
A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Timber Pharmaceuticals Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04154293
- Locations
- 🇺🇸
Minnesota Clinical Study Center, New Brighton, Minnesota, United States
🇺🇸Yale Center for Clinical Investigation, New Haven, Connecticut, United States
🇺🇸Austin Institute for Clinical Research, Inc, Metairie, Louisiana, United States
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: DexrazoxaneBiological: DinutuximabDrug: DoxorubicinDrug: EtoposideRadiation: External Beam Radiation TherapyDrug: IsotretinoinDrug: MelphalanBiological: SargramostimDrug: ThiotepaDrug: TopotecanDrug: Vincristine
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT03786783
- Locations
- 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇳🇿Starship Children's Hospital, Grafton, Auckland, New Zealand
🇦🇺The Children's Hospital at Westmead, Westmead, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.